CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary

CannaPharmaRx reported 3Q 2026 revenue of $137.71K, down 79% YoY, with net income of $645.42K, reversing a prior loss. Lower sales volumes, including no Cantek sales, drove revenue decline, while non-cash gains improved earnings. The company has $32,037 in cash and a $30.93M working-capital deficiency, with management expressing doubt about its ability to continue operations.

Original reporting
Published Nov 17, 2026, 1:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CannaPharmaRx 3Q 2026: Revenue $137.71K, EPS ($0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

$CPMDBearishMed
01

Why it matters

For traders, the key decision inputs are the magnitude of the sales decline, the operating expense changes, and the explicit going-concern doubt tied to very low cash and a large working-capital deficiency.

02

Market read

This is a distressed-company quarterly disclosure with explicit going-concern risk, which can drive near-term repricing and financing/dilution speculation.

03

What to watch

The company cites capacity expansion plans (10 growing rooms, additional drying/packing) that could support future volumes if liquidity is secured, partially offsetting near-term distress.

Relevance 6/10Novelty 6/10Timing: today’s 10-Q summary (Nov. 17, 2026)

Background

The piece summarizes CannaPharmaRx’s 3Q 2026 Form 10-Q, focusing on revenue collapse, operating loss, and liquidity/going-concern language.

Company-level read

Ticker impact

$CPMDBearishMedium confidence
Context

CannaPharmaRx reports 3Q 2026 revenue down 79% and a going-concern warning, with cash of $32,037 and a large working-capital deficiency.

Expected impact

Likely downside pressure as traders price in going-concern risk and potential financing/dilution needs.

Evidence & confidence

The article’s newest facts are the quarter’s revenue/EPS swing and explicit going-concern language, plus very low cash versus a large working-capital deficit.

Market effects

Reinforces weak demand and financing fragility in small-cap cannabis producers, potentially weighing on peer sentiment.

Limited, mostly affects US microcap cannabis names with similar balance-sheet risk.

Low, company-specific filing with no stated cross-border catalyst.

Counterpoint

Non-cash fair-value gains and derivative conversion features improved net income, so the headline profit may not reflect core operating strength.

Key entities

  • CannaPharmaRx, Inc.

    Reports 3Q 2026 revenue of $137.71K (down 79% YoY) and going-concern doubt in its 10-Q summary.

Related articles

$RIMEMed

Algorhythm Holdings Reports Third Quarter 2026 Financial Results

Algorhythm Holdings, Inc. (RIME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Algorhythm Holdings Reports Third Quarter 2026 Financial Results Company Completes Azure Energy Acquisition and Begins Strategic Restructuring Fort Lauderdale, FL, November 17, 2026 – Algorhythm Holdings, Inc. (the “Company”) (NASDAQ: RIME ), a diversified holding co

$PULMMed

Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. (PULM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger Merger with Eos SENOLYTIX expected to close by end of the year Framingham, Mass., November 17, 2026 – Pulmatrix, Inc. (“Pulmatrix”, the “Company” or “our”) (Nasdaq: PULM), a biopharmaceut

$PPSIMed

Pioneer Power Reports Q3 Gross Margin of 23.1% and Non-GAAP Operating Income of $321,000

Pioneer Power reported Q3 2026 revenue of $5.1M, down from $6.9M YoY, but gross margin improved to 23.1% from 9.3%. Operating loss was $2.8M, including a $1.4M non-cash impairment charge. Non-GAAP operating income was $321K. The company expects $15M in second-half revenue, up over 60% from the first half. Backlog increased 41.7% YoY to $17.9M. Revenue decline attributed to lower e-Boost sales and shipment delays.

$CNTMMed

ConnectM Reports 9% Revenue Growth to $8.9 Million, 139% Growth in Core Businesses and 28% Improvement in Operating Loss for Third Quarter 2026

ConnectM Technology Solutions, Inc. (CNTM) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 ConnectM Reports 9% Revenue Growth to $8.9 Million, 139% Growth in Core Businesses and 28% Improvement in Operating Loss for Third Quarter 2026 MARLBOROUGH, Mass., Nov. 17, 2026 (GLOBE NEWSWIRE) -- ConnectM Technology Solutions, Inc. (OTCQX: CNTM) (“ConnectM” or the